CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Previously reported	Retroactive application of recapitalization	Legacy Common Stock	Legacy Common Stock Previously reported	Legacy Common Stock Retroactive application of recapitalization	Legacy Preferred Stock	Legacy Preferred Stock Previously reported	Legacy Preferred Stock Retroactive application of recapitalization	Common Stock	Common Stock Previously reported	Common Stock Retroactive application of recapitalization	Additional Paid-in Capital	Additional Paid-in Capital Previously reported	Additional Paid-in Capital Retroactive application of recapitalization	Note Receivable from Stockholder	Note Receivable from Stockholder Previously reported	Note Receivable from Stockholder Retroactive application of recapitalization	Accumulated other Comprehensive Income (Loss)	Accumulated other Comprehensive Income (Loss) Previously reported	Accumulated other Comprehensive Income (Loss) Retroactive application of recapitalization	Accumulated Deficit	Accumulated Deficit Previously reported	Accumulated Deficit Retroactive application of recapitalization
Beginning balance (in shares) at Dec. 31, 2020				0	54,358	(54,358)	0	931	(931)	35,501,743	0	35,501,743
Beginning balance at Dec. 31, 2020	$ (29,960)	$ (29,960)	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 4	$ 0	$ 4	$ 13,952	$ 13,956	$ (4)	$ (554)	$ (554)	$ 0	$ 242	$ 242	$ 0	$ (43,604)	$ (43,604)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	34												34
Net income (loss)	(3,274)																					(3,274)
Foreign currency translation adjustments	(5)																		(5)
Ending balance (in shares) at Mar. 31, 2021										35,501,743
Ending balance at Mar. 31, 2021	(33,205)									$ 4			13,986			(554)			237			(46,878)
Beginning balance (in shares) at Dec. 31, 2021										150,598,047
Beginning balance at Dec. 31, 2021	302,297									$ 16			722,250			0			(1,257)			(418,712)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for vesting of restricted stock units (in shares)										5,184
Stock-based compensation	7,049												7,049
Net income (loss)	32,507																					32,507
Foreign currency translation adjustments	(145)																		(145)
Ending balance (in shares) at Mar. 31, 2022										150,603,231
Ending balance at Mar. 31, 2022	$ 341,708									$ 16			$ 729,299			$ 0			$ (1,402)			$ (386,205)